Chloe Reble
Colorectal Cancer (CRC) remains a significant health burden globally, with metastatic disease posing a considerable challenge in management and prognosis. The KRAS gene mutation, particularly the G12C mutation, has garnered attention for its role in driving CRC progression. This article explores the association between KRAS G12C status and the age at onset of metastatic CRC. Understanding this association is crucial for personalized treatment strategies and improving outcomes in CRC patients, Colorectal Cancer (CRC) is one of the most prevalent malignancies worldwide, with a substantial impact on morbidity and mortality. While early detection and treatment have improved outcomes, metastatic CRC presents a formidable challenge due to its advanced stage at diagnosis and limited treatment options. KRAS mutations, particularly the G12C mutation, have emerged as significant drivers of CRC progression, influencing disease aggressiveness and therapeutic response. This article aims to examine the relationship between KRAS G12C status and the age at onset of metastatic CRC, shedding light on its implications for clinical management
PDFShare this article
Journal of Clinical & Medical Genomics received 391 citations as per Google Scholar report
